Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia (Q34131844)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

16

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

31 July 2017

Alessandra Ferrajoli

5

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

31 July 2017

3

object named as

Stefan Faderl

1 reference

Europe PubMed Central

31 July 2017

Srdan Verstovsek

8

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

31 July 2017

William G Wierda

6

object named as

William Wierda

1 reference

Europe PubMed Central

31 July 2017

Jorge Eduardo Cortes

15

object named as

Jorge Cortes

1 reference

Europe PubMed Central

31 July 2017

2

object named as

Susan O'Brien

1 reference

Europe PubMed Central

31 July 2017

7

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

31 July 2017

12

object named as

Sherry Pierce

1 reference

Europe PubMed Central

31 July 2017

Guillermo Garcia-Manero

4

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

31 July 2017

Michael Andreeff

11

object named as

Michael Andreeff

1 reference

Europe PubMed Central

31 July 2017

Michael J. Keating

14

object named as

Michael J Keating

1 reference

Europe PubMed Central

31 July 2017

Rebecca S Garris

13

object named as

Rebecca Garris

1 reference

Europe PubMed Central

31 July 2017

Jeffrey C. Jorgensen

9

object named as

Jeffrey L Jorgensen

1 reference

Europe PubMed Central

31 July 2017

Carlos B Bueso-Ramos

10

object named as

Carlos Bueso-Ramos

1 reference

Europe PubMed Central

31 July 2017

author name string

Deborah A Thomas

1

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

26 July 2010

1 reference

Europe PubMed Central

31 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

31 July 2017

28

1 reference

Europe PubMed Central

31 July 2017

24

1 reference

Europe PubMed Central

31 July 2017

3880-3889

1 reference

Europe PubMed Central

31 July 2017

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

5 July 2018

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940403

28 October 2018

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.26.9456

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34131844&oldid=1978995012"